Literature DB >> 19412963

Recurrent acute dystonic reaction and oculogyric crisis despite withdrawal of dopamine receptor blocking drugs.

Susanne A Schneider1, Vrajesh Udani, Charulata Sawant Sankhla, Kailash P Bhatia.   

Abstract

Adverse events of dopamine-blocking agents include acute dystonic reactions and oculogyric crises (OGCs). OGCs may be recurrent on maintenance of or re-exposure to the drug. Thus, complete withdrawal is recommended. Recurrent episodes of acute dystonia despite withdrawal and the lack of further exposure to antidopaminergic agents are usually not seen. Here, we report three cases with recurrent OGCs despite complete withdrawal of neuroleptics. Triggering or priming factors were a single dose of haloperidol in two cases and a single dose of metoclopramide in one case. Episodes reoccurred spontaneously, but responded to anticholinergics. The pathomechanisms of acute dystonic reactions and OGCs remain unclear. Parallels to levodopa-induced dyskinesias in Parkinson's disease, as well as to dopa-responsive dystonia, paroxysmal dyskinesias, and channelopathies are discussed here. Whether there is a genetic susceptibility or some other reason for only some patients developing this phenomenon remains unclear. (c) 2009 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19412963     DOI: 10.1002/mds.22532

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  3 in total

1.  Oculogyric Crisis with Downward Deviation - A Photo Essay.

Authors:  Hüseyin Nezih Özdemir; Neşe Çelebisoy
Journal:  Neuroophthalmology       Date:  2018-03-26

Review 2.  Spotlight on Oculogyric Crisis: A Review.

Authors:  Pankaj Mahal; Navratan Suthar; Naresh Nebhinani
Journal:  Indian J Psychol Med       Date:  2020-09-03

3.  Clinical characteristics of acute drug-induced dystonia in pediatric patients.

Authors:  Hyun Woong Park; Jae Ryung Kwak; Ji Sook Lee
Journal:  Clin Exp Emerg Med       Date:  2017-09-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.